Viral reduction of human blood by ultraviolet A‐photosensitized vitamin K5

Abstract

Blood product transfusion can transmit viral pathogens. Pathogen reduction methods for blood products have been developed but, so far, are not available for whole blood. We evaluated if vitamin K5 (VK5) and ultraviolet A (UVA) irradiation could be used for virus inactivation in plasma and whole blood. Undiluted human plasma and whole blood diluted to 20% were spiked with high levels of vaccinia or Zika viruses. Infectious titers were measured by standard TCID50 assay before and after VK5/UVA treatments. Up to 3.6\u2009log of vaccinia and 3.2\u2009log of Zika were reduced in plasma by the combination of 500\u2009μM VK5 and 3\u2009J/cm2 UVA, and 3.1\u2009log of vaccinia and 2.9\u2009log of Zika were reduced in diluted human blood (20%) by the combination of 500\u2009μM VK5 and 70\u2009J/cm2 UVA. At end of whole blood treatment, hemolysis increased from 0.18% to 0.41% but remained below 1% hemolysis, which is acceptable to the Food and Drug Administration for red cell transfusion products. No significant alteration of biochemical parameters of red blood cells occurred with treatment. Our results provide proof of the concept that a viral pathogen reduction method based on VK5/UVA may be developed for whole blood.